FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3093603721> ?p ?o ?g. }

• W3093603721 endingPage "e855" @default.
• W3093603721 startingPage "e855" @default.
• W3093603721 abstract "We evaluated if PSA response measured at 6 months after commencement of treatment predicts better clinical outcomes in patients with localized high-risk prostate cancer (HRPC) enrolled in a randomized trial (PCS4) and treated with androgen deprivation therapy (ADT) and radiotherapy (RT). A total of 547 patients with HRPC received ADT and RT. All patients received the same RT dose and were randomized to receive ADT for a total duration of either 18 or 36 months. ADT began 4 months before RT. Serum PSA was measured initially before ADT and then regularly during the follow-up period. Patients achieving a PSA level below the cut-off values of 0.1 or 0.2 ng/mL at 6 months were compared to those who did not reach these values. Clinical outcomes analyzed were biochemical failure (BF), prostate cancer progression (PCP), metastasis free survival (MFS) and overall survival (OS). BF and PCP were analyzed considering death as a competing event. Proportional sub distribution hazard models were used to estimate hazard ratios (HRs). HRs for MFS and OS were estimated with Cox models. Using the PSA cut-off of 0.1 ng/mL, 34.4% of patients achieved a PSA response of <0.1 at 6 months. At a median follow-up of 13.23 years, 17.0% of patients with PSA <0.1 developed BF compared to 35.9% for those with a PSA >0.1 [HR = 2.46 (1.68 to 3.61), p = <0.001]. Similarly, 8.5% of patients with PSA <0.1 developed PCP compared to 17.3% from the PSA >0.1 cohort [HR = 2.15 (1.24 to 3.71), p = 0.006]. Using the PSA cut-off of 0.2 ng/mL, fewer BF [HR = 3.12 (2.26 to 4.31), p = <0.001] and lower PCP [2.55 (1.61 to 4.02), p = <0,001] were also seen in the 58% of patients achieving a PSA <0.2 compared to those with a PSA >0.2. In multivariable Cox models, including treatment arm, baseline PSA and baseline Gleason score, association of PSA at 6 months for either cut-off remains significant for BF and PCP. None of the two PSA cut-off at 6 months was statistically associated with MFS or OS.MFS: HR for cut-off 0.1 was 0.92 (0.73 to 1.56), p = 0.457 while HR for cut-off 0.2 was 1.08 (0.86 to 1.36), p = 0.494 OS: HR for cut-off 0.1 was 0.85 (0.68-1.08), p = 0.181, while HR for cut-off 0.2 was 1.02 (0.81-1.28), p = 0.894. In a cohort of patients exclusively with HRPC treated with RT and ADT, a PSA response of <0.1 ng/ml or <0.2 ng/ml at 6 months post-ADT predicts fewer BF and lower PCP. These data suggest that patients remaining with a higher PSA after 6 months of ADT may harbor a more aggressive genetic phenotype and should be considered for trials testing new therapeutic strategies earlier on." @default.
• W3093603721 created "2020-10-29" @default.
• W3093603721 creator A5001576092 @default.
• W3093603721 creator A5019527975 @default.
• W3093603721 creator A5020598292 @default.
• W3093603721 creator A5024741202 @default.
• W3093603721 creator A5027269011 @default.
• W3093603721 creator A5036530578 @default.
• W3093603721 creator A5042661444 @default.
• W3093603721 creator A5055458378 @default.
• W3093603721 creator A5063841558 @default.
• W3093603721 creator A5066865022 @default.
• W3093603721 creator A5077146779 @default.
• W3093603721 creator A5079343581 @default.
• W3093603721 creator A5091337701 @default.
• W3093603721 date "2020-11-01" @default.
• W3093603721 modified "2023-10-17" @default.
• W3093603721 title "Outcomes Comparison Using PSA Cut-Off Values Of 0.1 Or 0.2 Ng/Ml At 6 Months In Localized High-Risk Prostate Cancer Treated With Androgen Deprivation Therapy And Radiotherapy: Prospective Data From A Phase III Trial" @default.
• W3093603721 doi "https://doi.org/10.1016/j.ijrobp.2020.07.416" @default.
• W3093603721 hasPublicationYear "2020" @default.
• W3093603721 type Work @default.
• W3093603721 sameAs 3093603721 @default.
• W3093603721 citedByCount "0" @default.
• W3093603721 crossrefType "journal-article" @default.
• W3093603721 hasAuthorship W3093603721A5001576092 @default.
• W3093603721 hasAuthorship W3093603721A5019527975 @default.
• W3093603721 hasAuthorship W3093603721A5020598292 @default.
• W3093603721 hasAuthorship W3093603721A5024741202 @default.
• W3093603721 hasAuthorship W3093603721A5027269011 @default.
• W3093603721 hasAuthorship W3093603721A5036530578 @default.
• W3093603721 hasAuthorship W3093603721A5042661444 @default.
• W3093603721 hasAuthorship W3093603721A5055458378 @default.
• W3093603721 hasAuthorship W3093603721A5063841558 @default.
• W3093603721 hasAuthorship W3093603721A5066865022 @default.
• W3093603721 hasAuthorship W3093603721A5077146779 @default.
• W3093603721 hasAuthorship W3093603721A5079343581 @default.
• W3093603721 hasAuthorship W3093603721A5091337701 @default.
• W3093603721 hasConcept C121608353 @default.
• W3093603721 hasConcept C126322002 @default.
• W3093603721 hasConcept C126894567 @default.
• W3093603721 hasConcept C143998085 @default.
• W3093603721 hasConcept C168563851 @default.
• W3093603721 hasConcept C188816634 @default.
• W3093603721 hasConcept C207103383 @default.
• W3093603721 hasConcept C2777899217 @default.
• W3093603721 hasConcept C2780192828 @default.
• W3093603721 hasConcept C44249647 @default.
• W3093603721 hasConcept C50382708 @default.
• W3093603721 hasConcept C509974204 @default.
• W3093603721 hasConcept C71924100 @default.
• W3093603721 hasConceptScore W3093603721C121608353 @default.
• W3093603721 hasConceptScore W3093603721C126322002 @default.
• W3093603721 hasConceptScore W3093603721C126894567 @default.
• W3093603721 hasConceptScore W3093603721C143998085 @default.
• W3093603721 hasConceptScore W3093603721C168563851 @default.
• W3093603721 hasConceptScore W3093603721C188816634 @default.
• W3093603721 hasConceptScore W3093603721C207103383 @default.
• W3093603721 hasConceptScore W3093603721C2777899217 @default.
• W3093603721 hasConceptScore W3093603721C2780192828 @default.
• W3093603721 hasConceptScore W3093603721C44249647 @default.
• W3093603721 hasConceptScore W3093603721C50382708 @default.
• W3093603721 hasConceptScore W3093603721C509974204 @default.
• W3093603721 hasConceptScore W3093603721C71924100 @default.
• W3093603721 hasIssue "3" @default.
• W3093603721 hasLocation W30936037211 @default.
• W3093603721 hasOpenAccess W3093603721 @default.
• W3093603721 hasPrimaryLocation W30936037211 @default.
• W3093603721 hasRelatedWork W1992247710 @default.
• W3093603721 hasRelatedWork W2039377589 @default.
• W3093603721 hasRelatedWork W2466734156 @default.
• W3093603721 hasRelatedWork W2529939135 @default.
• W3093603721 hasRelatedWork W2793295628 @default.
• W3093603721 hasRelatedWork W2898154622 @default.
• W3093603721 hasRelatedWork W2911627432 @default.
• W3093603721 hasRelatedWork W2942831260 @default.
• W3093603721 hasRelatedWork W4220991042 @default.
• W3093603721 hasRelatedWork W4250238380 @default.
• W3093603721 hasVolume "108" @default.
• W3093603721 isParatext "false" @default.
• W3093603721 isRetracted "false" @default.
• W3093603721 magId "3093603721" @default.
• W3093603721 workType "article" @default.